Amarin Corporation plc - Press Releaseshttp://investor.amarincorp.com/releases.cfm?sh_auth=0.0.0.ad1dcb691ef81696c0c02ea27e385165en-usShareholder.com RSS FeedAmarin Informed by FDA of October 16th Advisory Committee Date in Connection With Supplemental New Drug Application (sNDA) for Vascepa(R) in the Treatment of Patients With High Triglycerides (>200 mg/dL and <500 mg/dL) With Mixed Dyslipidemiahttp://investor.amarincorp.com/releasedetail.cfm?ReleaseID=772349Wed, 19 Jun 2013 11:59:00 GMThttp://investor.amarincorp.com/releasedetail.cfm?ReleaseID=772349Amarin Informed by FDA of October 16th Advisory Committee Date in Connection With Supplemental New Drug Application (sNDA) for Vascepa(R) in the Treatment of Patients With High Triglycerides (>200 mg/dL and <500 mg/dL) With Mixed DyslipidemiaAmarin to Present at the Jefferies 2013 Global Healthcare Conferencehttp://investor.amarincorp.com/releasedetail.cfm?ReleaseID=768248Thu, 30 May 2013 20:05:00 GMThttp://investor.amarincorp.com/releasedetail.cfm?ReleaseID=768248Amarin to Present at the Jefferies 2013 Global Healthcare ConferenceAmarin Announces Additional Effects of Vascepa(R) on Lipoprotein Particle Concentration From the ANCHOR Study Presented at the National Lipid Association 2013 Annual Scientific Sessionshttp://investor.amarincorp.com/releasedetail.cfm?ReleaseID=768023Thu, 30 May 2013 10:00:00 GMThttp://investor.amarincorp.com/releasedetail.cfm?ReleaseID=768023Amarin Announces Additional Effects of Vascepa(R) on Lipoprotein Particle Concentration From the ANCHOR Study Presented at the National Lipid Association 2013 Annual Scientific SessionsAmarin Announces Notification of Patent Allowance for U.S. Application 13/417,899 Related to Combination Product of Vascepa(R) and Statin Therapyhttp://investor.amarincorp.com/releasedetail.cfm?ReleaseID=766440Wed, 22 May 2013 10:00:00 GMThttp://investor.amarincorp.com/releasedetail.cfm?ReleaseID=766440Amarin Announces Notification of Patent Allowance for U.S. Application 13/417,899 Related to Combination Product of Vascepa(R) and Statin TherapyAmarin Reports First Quarter 2013 Financial Results and Provides Update on Operationshttp://investor.amarincorp.com/releasedetail.cfm?ReleaseID=763653Thu, 09 May 2013 20:05:00 GMThttp://investor.amarincorp.com/releasedetail.cfm?ReleaseID=763653Amarin Reports First Quarter 2013 Financial Results and Provides Update on OperationsAmarin to Report First Quarter 2013 Results and Host Conference Call on May 9, 2013http://investor.amarincorp.com/releasedetail.cfm?ReleaseID=761935Fri, 03 May 2013 20:00:00 GMThttp://investor.amarincorp.com/releasedetail.cfm?ReleaseID=761935Amarin to Report First Quarter 2013 Results and Host Conference Call on May 9, 2013Amarin Announces Approval of Supplemental New Drug Application for BASF as Additional Vascepa(R) Active Pharmaceutical Ingredient Supplierhttp://investor.amarincorp.com/releasedetail.cfm?ReleaseID=760314Tue, 30 Apr 2013 10:00:00 GMThttp://investor.amarincorp.com/releasedetail.cfm?ReleaseID=760314Amarin Announces Approval of Supplemental New Drug Application for BASF as Additional Vascepa(R) Active Pharmaceutical Ingredient SupplierAmarin Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for Vascepa(R) for the Treatment of Patients With High Triglycerides (>200 mg/dL and <500 mg/dL) With Mixed Dyslipidemiahttp://investor.amarincorp.com/releasedetail.cfm?ReleaseID=758322Tue, 23 Apr 2013 10:00:00 GMThttp://investor.amarincorp.com/releasedetail.cfm?ReleaseID=758322Amarin Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for Vascepa(R) for the Treatment of Patients With High Triglycerides (>200 mg/dL and <500 mg/dL) With Mixed DyslipidemiaAmarin Announces Approval of Supplemental New Drug Application for Chemport as Additional Vascepa(R) Active Pharmaceutical Ingredient Supplierhttp://investor.amarincorp.com/releasedetail.cfm?ReleaseID=757342Thu, 18 Apr 2013 10:00:00 GMThttp://investor.amarincorp.com/releasedetail.cfm?ReleaseID=757342Amarin Announces Approval of Supplemental New Drug Application for Chemport as Additional Vascepa(R) Active Pharmaceutical Ingredient SupplierAmarin Announces New Clinical Data Showing Significant Reductions in Apolipoprotein C-III Levels in MARINE and ANCHOR Studies of Vascepa(R)http://investor.amarincorp.com/releasedetail.cfm?ReleaseID=754807Mon, 08 Apr 2013 10:00:00 GMThttp://investor.amarincorp.com/releasedetail.cfm?ReleaseID=754807Amarin Announces New Clinical Data Showing Significant Reductions in Apolipoprotein C-III Levels in MARINE and ANCHOR Studies of Vascepa(R)